Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · IEX Real-Time Price · USD
3.710
+0.190 (5.40%)
At close: Jul 26, 2024, 4:00 PM
3.850
+0.140 (3.77%)
After-hours: Jul 26, 2024, 7:01 PM EDT
Can-Fite BioPharma Revenue
In the year 2023, Can-Fite BioPharma had annual revenue of 743.00K ILS, down -8.27%. Can-Fite BioPharma had revenue of 155.00K in the quarter ending December 31, 2023, a decrease of -21.32%.
Revenue (ttm)
743.00K ILS
Revenue Growth
-8.27%
P/S Ratio
29.59
Revenue / Employee
92,875 ILS
Employees
8
Market Cap
21.99M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 713.56M |
Meihua International Medical Technologies Co. | 97.10M |
SAB Biotherapeutics | 2.60M |
Femasys | 1.05M |
Biora Therapeutics | 544.00K |
CANF News
- 9 days ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8 - GlobeNewsWire
- 15 days ago - Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix - Business Wire
- 4 weeks ago - Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver - Business Wire
- 6 weeks ago - Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study - Business Wire
- 7 weeks ago - Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study - Business Wire
- 2 months ago - Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases - Business Wire
- 2 months ago - Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 - Business Wire